patients with solid malignancies. However, given the changing landscape of personalized treatments for many solid malignancies, the voting panel felt that a generalized recommendation was not possible. On February 4, 2021, the FDA released a Drug Safety Alert noting a possible increased risk of major cardiovascular events and malignancies (excluding non-melanoma skin cancer) in patients with RA (over the age of 50 years with at least 1 risk factor for cardiovascular disease) participating in a